Avalyn Pharma (NASDAQ:AVLN) Trading Up 8.2% Following Better-Than-Expected Earnings

Key Points

• Avalyn Pharma shares rose 8.2% to $38.35 after the company reported a quarterly loss of $0.98 per share, beating analyst expectations by $0.05. Trading volume was approximately 87,139 shares, 75% below the average.
• Analysts remain broadly positive, with the stock carrying an average “Buy” rating and a $59 price target. Recent coverage included price targets ranging from $51 to $80.
• Bank of New York Mellon initiated a position of 40,140 shares valued at roughly $1.32 million. Avalyn is a clinical-stage biopharmaceutical company developing inhaled treatments for serious respiratory diseases, including pulmonary fibrosis.

Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) shares were up 8.2% during mid-day trading on Wednesday following a better than expected earnings announcement. The company traded as high as $39.04 and last traded at $38.35. Approximately 87,139 shares were traded during mid-day trading, a decline of 75% from the average daily volume of 347,286 shares. The stock had previously closed at $35.46.

The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.05.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on AVLN. Guggenheim started coverage on shares of Avalyn Pharma in a research note on Monday, May 25th. They issued a "buy" rating and a $80.00 target price for the company. Jefferies Financial Group started coverage on shares of Avalyn Pharma in a report on Monday, May 25th. They set a "buy" rating and a $52.00 target price for the company. Wall Street Zen upgraded shares of Avalyn Pharma to a "hold" rating in a report on Saturday, May 9th. Evercore assumed coverage on shares of Avalyn Pharma in a report on Tuesday, May 26th. They issued an "outperform" rating and a $51.00 price objective for the company. Finally, Zacks Research raised Avalyn Pharma to a "hold" rating in a research report on Wednesday, May 27th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $59.00.

Hedge Funds Weigh In On Avalyn Pharma

A hedge fund recently bought a new stake in Avalyn Pharma stock. Bank of New York Mellon Corp bought a new stake in Avalyn Pharma Inc. (NASDAQ:AVLN - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 40,140 shares of the company's stock, valued at approximately $1,321,000. Bank of New York Mellon Corp owned approximately 0.09% of Avalyn Pharma at the end of the most recent reporting period.

Avalyn Pharma Price Performance

The stock has a market capitalization of $1.69 billion and a P/E ratio of -1.74. The firm's 50-day moving average is $29.49.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source